Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CEMI Chembio Diagnostics (CEMI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Chembio Diagnostics Stock (NASDAQ:CEMI) 30 days 90 days 365 days Advanced Chart Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Chembio Diagnostics alerts:Sign Up Key Stats Today's Range$0.45▼$0.4650-Day Range$0.33▼$0.4652-Week Range$0.19▼$1.24Volume351,642 shsAverage Volume661,416 shsMarket Capitalization$16.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewChembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.Read More… 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Receive CEMI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address CEMI Stock News HeadlinesANY LAB TEST NOW Forms Strategic Partnership with ChembioApril 17, 2024 | finance.yahoo.comQuest Diagnostics Inc DGXNovember 2, 2023 | morningstar.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…November 21, 2024 | WealthPress (Ad)Qualigen Therapeutics Sells FastPack Diagnostics Business to ChembioJuly 24, 2023 | marketwatch.comBiosynex Completes Acquisition of Chembio Diagnostics, Inc.April 27, 2023 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Laboratory (LH), Arbutus Biopharma (ABUS) and Chembio Diagnostics (CEMI)April 27, 2023 | markets.businessinsider.comShareholder Alert: Ademi LLP investigates whether Chembio Diagnostics, Inc. has obtained a Fair Price in its transaction with BiosynexApril 20, 2023 | benzinga.comChembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023April 19, 2023 | finance.yahoo.comSee More Headlines CEMI Stock Analysis - Frequently Asked Questions How were Chembio Diagnostics' earnings last quarter? Chembio Diagnostics, Inc. (NASDAQ:CEMI) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.05. The business earned $12.06 million during the quarter. Chembio Diagnostics had a negative trailing twelve-month return on equity of 113.57% and a negative net margin of 47.03%. What other stocks do shareholders of Chembio Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), NovoCure (NVCR), BlackRock Capital Investment (BKCC), Viper Energy (VNOM) and Summit Midstream Partners (SMLP). Company Calendar Last Earnings11/04/2021Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CEMI CUSIPN/A CIK1092662 Webwww.chembio.com Phone(631) 924-1135Fax631-924-2065Employees337Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,290,000.00 Net Margins-47.03% Pretax Margin-46.96% Return on Equity-113.57% Return on Assets-38.22% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.04 Sales & Book Value Annual Sales$48.34 million Price / Sales0.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book0.95Miscellaneous Outstanding Shares36,726,000Free Float35,514,000Market Cap$16.71 million OptionableNot Optionable Beta1.85 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:CEMI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chembio Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chembio Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.